Press release
August 12, 2026
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
Protalix BioTherapeutics, Inc. (PLX)
Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio ® Total revenue climbed to $53.6 million, year to date,